wikimedia
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
GraphQL
BETA
Graphs
1
Q37692798-A1E75BD7-B4AB-4FDD-A701-BECA0494AFD4
Q37692798-A1E75BD7-B4AB-4FDD-A701-BECA0494AFD4
BestRank
Statement
http://www.wikidata.org/entity/statement/Q37692798-A1E75BD7-B4AB-4FDD-A701-BECA0494AFD4
Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R).
P2860
Q37692798-A1E75BD7-B4AB-4FDD-A701-BECA0494AFD4
BestRank
Statement
http://www.wikidata.org/entity/statement/Q37692798-A1E75BD7-B4AB-4FDD-A701-BECA0494AFD4
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
150b316b9af38188fd695751a669dbd5d938ceba
P2860
Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia.